Fidelity Investments’s Protara Therapeutics TARA Stock Holding History

Fidelity Investments’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$297K	Buy	57,095 +56,212	+6,366%	+$333K	﹤0.01%	3327
2025 Q4	$4.71K	Buy	883 +790	+849%	+$4.39K	﹤0.01%	4899
2025 Q3	$405	Buy	+93	New	+$301	﹤0.01%	5101
2023 Q3	–	Sell	-9	Closed	-$23	–	5507
2023 Q2	$23	Buy	+9	New	+$27	﹤0.01%	5150
2016 Q4	–	Sell	-3,936	Closed	-$1.47M	–	2709
2016 Q3	$1.47M	Hold	3,936	–	–	﹤0.01%	2413
2016 Q2	$1.26M	Sell	3,936 -11,558	-75%	-$3.46M	﹤0.01%	2446
2016 Q1	$4.8M	Sell	15,494 -5,756	-27%	-$1.86M	﹤0.01%	2173
2015 Q4	$13.2M	Hold	21,250	–	–	﹤0.01%	1868
2015 Q3	$11.8M	Hold	21,250	–	–	﹤0.01%	1886
2015 Q2	$15.2M	Hold	21,250	–	–	﹤0.01%	1850
2015 Q1	$9.89M	Hold	21,250	–	–	﹤0.01%	2000
2014 Q4	$8.84M	Buy	+21,250	New	+$8.57M	﹤0.01%	2043

Other funds holding TARA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Fidelity Investments's TARA Position: Q1 2026 in Review

Fidelity Investments increased its Protara Therapeutics (TARA) stake by 6,366% in Q1 2026, buying an estimated $333K and bringing the position to 57,095 shares worth $297K. The position accounts for ﹤0.01% of the portfolio, ranked #3327.

Fidelity Investments first reported a position in TARA in Q4 2014 and has held it in 12 quarters since. The position peaked at $15.2M in Q2 2015. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

Fidelity Investments held 57,095 shares of Protara Therapeutics worth $297K as of Q1 2026.
Fidelity Investments bought 56,212 Protara Therapeutics shares in Q1 2026, an estimated $333K.
Protara Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #3327 holding.
Fidelity Investments first reported a position in Protara Therapeutics in Q4 2014 and has held it in 12 quarters since.
Fidelity Investments's Protara Therapeutics position peaked at $15.2M in Q2 2015.
114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.